CAR T-cell therapy for GPNMB-positive solid tumours
Treatments studied
Part of Cancer, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called GPNMB found on some tumour types. It's for people with advanced alveolar soft part sarcoma, certain kidney cancers, or triple-negative breast cancer that hasn't responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your tumour must be a specific type: alveolar soft part sarcoma, non-clear cell kidney cancer, or triple-negative breast cancer.
- A central lab must confirm your tumour has high levels of a protein called GPNMB.
- Your cancer must be advanced or have come back after treatment, with no standard cure available.
- You must have had at least one prior treatment (and sometimes more) depending on your cancer type.
- You need to be in fairly good health (able to do daily activities) and have no uncontrolled infections or serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called CAR T cells that are trained to find and attack cancer cells with a specific marker (GPC3). The CAR T cells are also 'armored' with extra proteins (IL-15 and IL-21) to help them work better. It might be an option for adults with advanced solid tumors, especially liver cancer, that have not responded to standard treatments.
This trial tests a new type of immunotherapy called CAR T-cells (C-CAR031) for people with advanced squamous cell lung cancer that has a specific marker called GPC3. The treatment involves collecting your own immune cells, modifying them to attack cancer, and infusing them back into your body.
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
This trial tests a personalized immune-cell treatment (CAR T) built from your own blood lymphocytes. It targets cancers that show a marker called CD70, aiming to slow or stop the cancer when other treatments didn’t work.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This trial tests a new CAR-T therapy designed to target specific proteins on cancer cells. It may be an option for people with advanced blood cancers (like multiple myeloma or lymphoma) or solid tumors (like small cell lung cancer) that have not responded to other treatments.
Hear when a new Alveolar Soft Part Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.